Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design and redesign journey of a drug for transthyretin amyloidosis

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties

  • Pinheiro, Francisca
  • Varejão, Nathalia
  • Sánchez-Morales, Adrià
  • Bezerra, Filipa
  • Navarro, Susanna
  • Velázquez-Campoy, Adrián
  • Busqué, Félix
  • Almeida, Maria Rosário
  • Alibés, Ramon
  • Reverter, David
  • Pallarès, Irantzu
  • Ventura, Salvador
The aggregation of wild-type transthyretin (TTR) and over 130 genetic TTR variants underlies a group of lethal disorders named TTR amyloidosis (ATTR). TTR chemical chaperones are molecules that hold great promise to modify the course of ATTR progression. In previous studies, we combined rational design and molecular dynamics simulations to generate a series of TTR selective kinetic stabilizers displaying exceptionally high affinities. In an effort to endorse the previously developed molecules with optimal pharmacokinetic properties, we conducted structural design optimization, leading to the development of PITB. PITB binds with high affinity to TTR, effectively inhibiting tetramer dissociation and aggregation of both the wild-type protein and the two most prevalent disease-associated TTR variants. Importantly, PITB selectively binds and stabilizes TTR in plasma, outperforming tolcapone, a drug currently undergoing clinical trials for ATTR. Pharmacokinetic studies conducted on mice confirmed that PITB exhibits encouraging pharmacokinetic properties, as originally intended. Furthermore, PITB demonstrates excellent oral bioavailability and lack of toxicity. These combined attributes position PITB as a lead compound for future clinical trials as a disease-modifying therapy for ATTR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of a highly potent transthyretin amyloidogenesis inhibitor, design, synthesis, and evaluation

  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Peccati, Francesca|||0000-0002-7813-8216
  • Sánchez-Morales, Adrià|||0000-0002-8692-0988
  • Varejão, Nathalia|||0000-0002-6952-8896
  • Bezerra, Filipa|||0000-0002-1675-2317
  • Ortega-Alarcon, David|||0000-0003-1885-4365
  • González, Danilo|||0000-0002-2316-2016
  • Osorio, Marcelo
  • Navarro, Susanna|||0000-0001-8160-9536
  • Velázquez-Campoy, Adrián|||0000-0001-5702-4538
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Busqué, Félix|||0000-0001-7566-4264
  • Alibés, Ramon|||0000-0002-7997-2691
  • Sodupe, Mariona|||0000-0003-0276-0524
  • Ventura, Salvador|||0000-0002-9652-6351
Transthyretin amyloidosis (ATTR) is a group of fatal diseases described by the misfolding and amyloid deposition of transthyretin (TTR). Discovering small molecules that bind and stabilize the TTR tetramer, preventing its dissociation and subsequent aggregation, is a therapeutic strategy for these pathologies. Departing from the crystal structure of TTR in complex with tolcapone, a potent binder in clinical trials for ATTR, we combined rational design and molecular dynamics (MD) simulations to generate a series of novel halogenated kinetic stabilizers. Among them, M-23 displays one of the highest affinities for TTR described so far. The TTR/ M-23 crystal structure confirmed the formation of unprecedented protein-ligand contacts, as predicted by MD simulations, leading to an enhanced tetramer stability both in vitro and in whole serum. We demonstrate that MD-assisted design of TTR ligands constitutes a new avenue for discovering molecules that, like M-23, hold the potential to become highly potent drugs to treat ATTR.